Research on XL228 from Exelixis

XL228 by Exelixis is a mulittargeted Kinase Inhibitor that targets several kinases including ALK. It has either completed or is near completing a phase I trial.

This entry was posted in Uncategorized. Bookmark the permalink.

2 Responses to Research on XL228 from Exelixis

  1. admin says:

    There are two phase I clinical trials for XL228. The first is for solid tumors (including NSCLC). See

    The second trial is for Leukemia. See .

  2. admin says:

    Here is a link to an ASCO abstract that summarizes the initial result from a Phase I trial of XL228. 41 patients were enrolled (having various kinds of tumors). Apparantly 5 of 9 (56%) of NSCLC patients experienced stable disease for greater than 12 weeks (up to 29 weeks). The abstract does not break out results by ALK status.

Leave a Reply